Trial Outcomes & Findings for Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer (NCT NCT01663727)

NCT ID: NCT01663727

Last Updated: 2019-01-22

Results Overview

Tumor assessment was performed as per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) by investigator. Disease progression was defined as at least 20 percent (%) increase in the sum of diameters of target lesions compared to smallest sum of diameters on-study and absolute increase of at least 5 millimeter (mm), unequivocal progression of existing non-target lesions, or presence of new lesions.

• Recruitment status: COMPLETED
• Study phase: PHASE3
• Target enrollment: 481 participants
• Primary outcome timeframe: Baseline, every 8 weeks until documented disease progression, death or clinical cut-off (up to 117.7 weeks)
• Results posted on: 2019-01-22

Participant Flow

Participant milestones

Measure	Paclitaxel+Placebo Participants received paclitaxel 90 mg/m\^2 IV on Days 1, 8 and 15 and placebo matched to bevacizumab IV infusion on Days 1 and 15 of a 28 day cycle until progressive disease, treatment limiting toxicity or death.	Paclitaxel+ Bevacizumab Participants received paclitaxel 90 mg/m\^2 IV on Days 1, 8 and 15 and bevacizumab IV 10 mg/kg on Days 1 and 15 of a 28 day cycle until progressive disease, treatment limiting toxicity or death.
Overall Study STARTED	242	239
Overall Study COMPLETED	0	1
Overall Study NOT COMPLETED	242	238

Reasons for withdrawal

Measure	Paclitaxel+Placebo Participants received paclitaxel 90 mg/m\^2 IV on Days 1, 8 and 15 and placebo matched to bevacizumab IV infusion on Days 1 and 15 of a 28 day cycle until progressive disease, treatment limiting toxicity or death.	Paclitaxel+ Bevacizumab Participants received paclitaxel 90 mg/m\^2 IV on Days 1, 8 and 15 and bevacizumab IV 10 mg/kg on Days 1 and 15 of a 28 day cycle until progressive disease, treatment limiting toxicity or death.
Overall Study Death	161	155
Overall Study Lost to Follow-up	10	8
Overall Study Withdrawal by Subject	18	25
Overall Study Study Terminated	51	50
Overall Study Withdrawal by subject and Adverse Event.	1	0
Overall Study Withdrawal prior to dosing.	1	0

Baseline Characteristics

Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer

Baseline characteristics by cohort

Measure	Paclitaxel+Placebo n=242 Participants Participants received paclitaxel 90 mg/m\^2 IV on Days 1, 8 and 15 and placebo matched to bevacizumab IV infusion on Days 1 and 15 of a 28 day cycle until progressive disease, treatment limiting toxicity or death.	Paclitaxel+ Bevacizumab n=239 Participants Participants received paclitaxel 90 mg/m\^2 IV on Days 1, 8 and 15 and bevacizumab IV 10 mg/kg on Days 1 and 15 of a 28 day cycle until progressive disease, treatment limiting toxicity or death.	Total n=481 Participants Total of all reporting groups
Age, Continuous	54.7 years STANDARD_DEVIATION 10.7 • n=5 Participants	55.8 years STANDARD_DEVIATION 11.5 • n=7 Participants	55.3 years STANDARD_DEVIATION 11.1 • n=5 Participants
Sex: Female, Male Female	237 Participants n=5 Participants	236 Participants n=7 Participants	473 Participants n=5 Participants
Sex: Female, Male Male	5 Participants n=5 Participants	3 Participants n=7 Participants	8 Participants n=5 Participants

PRIMARY outcome

Timeframe: Baseline, every 8 weeks until documented disease progression, death or clinical cut-off (up to 117.7 weeks)

Population: ITT population.

Tumor assessment was performed as per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) by investigator. Disease progression was defined as at least 20 percent (%) increase in the sum of diameters of target lesions compared to smallest sum of diameters on-study and absolute increase of at least 5 millimeter (mm), unequivocal progression of existing non-target lesions, or presence of new lesions.

Outcome measures

Measure	Paclitaxel+Placebo n=242 Participants Participants received paclitaxel 90 mg/m\^2 IV on Days 1, 8 and 15 and placebo matched to bevacizumab IV infusion on Days 1 and 15 of a 28 day cycle until progressive disease, treatment limiting toxicity or death.	Paclitaxel+ Bevacizumab n=239 Participants Participants received paclitaxel 90 mg/m\^2 IV on Days 1, 8 and 15 and bevacizumab IV 10 mg/kg on Days 1 and 15 of a 28 day cycle until progressive disease, treatment limiting toxicity or death.
Percentage of Participants With Progression or Death in Intent-to-Treat (ITT) Population	69.4 percentage of participants	63.6 percentage of participants

PRIMARY outcome

Timeframe: Baseline, every 8 weeks until documented disease progression, death or clinical cut-off (up to 117.7 weeks)

Population: ITT population.

PFS was defined as the interval between the date of randomization and the first documentation of progressive disease or death from any cause. Tumor assessment was performed as per RECIST v1.1 by investigator. Disease progression was defined as at least 20% increase in the sum of diameters of target lesions compared to smallest sum of diameters on-study and absolute increase of at least 5 mm, unequivocal progression of existing non-target lesions, or presence of new lesions. PFS was estimated using Kaplan Meier method.

Outcome measures

Measure	Paclitaxel+Placebo n=242 Participants Participants received paclitaxel 90 mg/m\^2 IV on Days 1, 8 and 15 and placebo matched to bevacizumab IV infusion on Days 1 and 15 of a 28 day cycle until progressive disease, treatment limiting toxicity or death.	Paclitaxel+ Bevacizumab n=239 Participants Participants received paclitaxel 90 mg/m\^2 IV on Days 1, 8 and 15 and bevacizumab IV 10 mg/kg on Days 1 and 15 of a 28 day cycle until progressive disease, treatment limiting toxicity or death.
Progression Free Survival (PFS) in ITT Population	8.8 months Interval 7.4 to 9.3	11.0 months Interval 9.5 to 12.2

PRIMARY outcome

Timeframe: Baseline, every 8 weeks until documented disease progression, death or clinical cut-off (up to 111.3 weeks)

Population: High baseline plasma VEGF-A ITT population: All participants randomized to study treatment with high baseline plasma VEGF-A levels (VEGF-A levels greater than or equal to 5.05 picograms per milliliter), irrespective of whether the assigned treatment was actually received.

Tumor assessment was performed as per RECIST v1.1 by investigator. Disease progression was defined as at least 20% increase in the sum of diameters of target lesions compared to smallest sum of diameters on-study and absolute increase of at least 5 mm, unequivocal progression of existing non-target lesions, or presence of new lesions.

Outcome measures

Measure	Paclitaxel+Placebo n=124 Participants Participants received paclitaxel 90 mg/m\^2 IV on Days 1, 8 and 15 and placebo matched to bevacizumab IV infusion on Days 1 and 15 of a 28 day cycle until progressive disease, treatment limiting toxicity or death.	Paclitaxel+ Bevacizumab n=120 Participants Participants received paclitaxel 90 mg/m\^2 IV on Days 1, 8 and 15 and bevacizumab IV 10 mg/kg on Days 1 and 15 of a 28 day cycle until progressive disease, treatment limiting toxicity or death.
Percentage of Participants With Progression or Death in High Baseline Plasma Vascular Endothelial Growth Factor-A (VEGF-A) ITT Population	75.0 percentage of participants	70.8 percentage of participants

PRIMARY outcome

Timeframe: Baseline, every 8 weeks until documented disease progression, death or clinical cut-off (up to 111.3 weeks)

Population: High baseline plasma VEGF-A ITT population.

PFS was defined as the interval between the date of randomization and the first documentation of progressive disease or death from any cause. Tumor assessment was performed as per RECIST v1.1 by investigator. Disease progression was defined as at least 20% increase in the sum of diameters of target lesions compared to smallest sum of diameters on-study and absolute increase of at least 5 mm, unequivocal progression of existing non-target lesions, or presence of new lesions. PFS was estimated using Kaplan Meier method.

Outcome measures

Measure	Paclitaxel+Placebo n=124 Participants Participants received paclitaxel 90 mg/m\^2 IV on Days 1, 8 and 15 and placebo matched to bevacizumab IV infusion on Days 1 and 15 of a 28 day cycle until progressive disease, treatment limiting toxicity or death.	Paclitaxel+ Bevacizumab n=120 Participants Participants received paclitaxel 90 mg/m\^2 IV on Days 1, 8 and 15 and bevacizumab IV 10 mg/kg on Days 1 and 15 of a 28 day cycle until progressive disease, treatment limiting toxicity or death.
PFS in High Baseline Plasma VEGF-A ITT Population	7.3 months Interval 5.6 to 8.7	9.6 months Interval 9.0 to 11.0

SECONDARY outcome

Timeframe: From randomization till death or clinical cut-off (up to 244 weeks)

Population: ITT Population.

Outcome measures

Measure	Paclitaxel+Placebo n=242 Participants Participants received paclitaxel 90 mg/m\^2 IV on Days 1, 8 and 15 and placebo matched to bevacizumab IV infusion on Days 1 and 15 of a 28 day cycle until progressive disease, treatment limiting toxicity or death.	Paclitaxel+ Bevacizumab n=239 Participants Participants received paclitaxel 90 mg/m\^2 IV on Days 1, 8 and 15 and bevacizumab IV 10 mg/kg on Days 1 and 15 of a 28 day cycle until progressive disease, treatment limiting toxicity or death.
Percentage of Participants Who Died - ITT Population	64.9 percentage of participants	64.0 percentage of participants

SECONDARY outcome

Timeframe: From randomization till death or clinical cut-off (up to 244 weeks)

Population: ITT population.

OS was defined as the interval between the date of randomization and death from any cause. OS was estimated using Kaplan Meier method.

Outcome measures

Measure	Paclitaxel+Placebo n=242 Participants Participants received paclitaxel 90 mg/m\^2 IV on Days 1, 8 and 15 and placebo matched to bevacizumab IV infusion on Days 1 and 15 of a 28 day cycle until progressive disease, treatment limiting toxicity or death.	Paclitaxel+ Bevacizumab n=239 Participants Participants received paclitaxel 90 mg/m\^2 IV on Days 1, 8 and 15 and bevacizumab IV 10 mg/kg on Days 1 and 15 of a 28 day cycle until progressive disease, treatment limiting toxicity or death.
Overall Survival (OS) - ITT Population	25.8 months Interval 21.8 to 30.2	28.8 months Interval 22.8 to 32.8

SECONDARY outcome

Timeframe: From randomization till death or clinical cut-off (up to 244 weeks)

Population: High Baseline Plasma VEGF-A ITT Population.

Outcome measures

Measure	Paclitaxel+Placebo n=124 Participants Participants received paclitaxel 90 mg/m\^2 IV on Days 1, 8 and 15 and placebo matched to bevacizumab IV infusion on Days 1 and 15 of a 28 day cycle until progressive disease, treatment limiting toxicity or death.	Paclitaxel+ Bevacizumab n=120 Participants Participants received paclitaxel 90 mg/m\^2 IV on Days 1, 8 and 15 and bevacizumab IV 10 mg/kg on Days 1 and 15 of a 28 day cycle until progressive disease, treatment limiting toxicity or death.
Percentage of Participants Who Died - High Baseline Plasma VEGF-A ITT Population	74.2 percentage of participants	71.1 percentage of participants

SECONDARY outcome

Timeframe: From randomization till death or clinical cut-off (up to 244 weeks)

Population: High Baseline Plasma VEGF-A ITT population.

OS was defined as the interval between the date of randomization and death from any cause. OS was estimated using Kaplan Meier method.

Outcome measures

Measure	Paclitaxel+Placebo n=124 Participants Participants received paclitaxel 90 mg/m\^2 IV on Days 1, 8 and 15 and placebo matched to bevacizumab IV infusion on Days 1 and 15 of a 28 day cycle until progressive disease, treatment limiting toxicity or death.	Paclitaxel+ Bevacizumab n=120 Participants Participants received paclitaxel 90 mg/m\^2 IV on Days 1, 8 and 15 and bevacizumab IV 10 mg/kg on Days 1 and 15 of a 28 day cycle until progressive disease, treatment limiting toxicity or death.
OS - High Baseline Plasma VEGF-A ITT Population	19.4 months Interval 16.5 to 25.0	22.8 months Interval 18.2 to 31.6

SECONDARY outcome

Timeframe: Baseline, every 8 weeks until documented disease progression, death or clinical cut-off (up to 117.7 weeks)

Population: Number of participants analyzed=participants from ITT population with measurable disease at baseline.

Objective response was defined as having a Complete Response (CR) or Partial Response (PR) according to a RECIST criteria v 1.1. CR was defined as disappearance of all target and non-target lesions and no new lesions, all pathological lymph nodes must have decreased to <10 mm in short axis and normalization of tumor marker level. PR was defined as at least a 30% decrease in the sum of diameters of target lesions (taking as reference the baseline sum diameters), no progression in non-target lesions, and no new lesions. Measurable disease was defined by the presence of at least one measurable lesion by clinical measurement, chest x-ray, computed tomography (CT), or magnetic resonance imaging (MRI).

Outcome measures

Measure	Paclitaxel+Placebo n=214 Participants Participants received paclitaxel 90 mg/m\^2 IV on Days 1, 8 and 15 and placebo matched to bevacizumab IV infusion on Days 1 and 15 of a 28 day cycle until progressive disease, treatment limiting toxicity or death.	Paclitaxel+ Bevacizumab n=202 Participants Participants received paclitaxel 90 mg/m\^2 IV on Days 1, 8 and 15 and bevacizumab IV 10 mg/kg on Days 1 and 15 of a 28 day cycle until progressive disease, treatment limiting toxicity or death.
Percentage of Participants With an Objective Response - ITT Population	33.2 percentage of participants Interval 26.87 to 39.49	54.0 percentage of participants Interval 47.09 to 60.83

SECONDARY outcome

Timeframe: Baseline, every 8 weeks until documented disease progression, death or clinical cut-off (up to 111.3 weeks)

Population: Number of participants analyzed=participants from high baseline plasma VEGF-A ITT population with measurable disease at baseline.

Objective response was defined as having a CR or PR according to a RECIST criteria v 1.1. CR was defined as disappearance of all target and non-target lesions and no new lesions, all pathological lymph nodes must have decreased to <10 mm in short axis and normalization of tumor marker level. PR was defined as at least a 30% decrease in the sum of diameters of target lesions (taking as reference the baseline sum diameters), no progression in non-target lesions, and no new lesions. Measurable disease was defined by the presence of at least one measurable lesion by clinical measurement, chest x-ray, CT, or MRI.

Outcome measures

Measure	Paclitaxel+Placebo n=116 Participants Participants received paclitaxel 90 mg/m\^2 IV on Days 1, 8 and 15 and placebo matched to bevacizumab IV infusion on Days 1 and 15 of a 28 day cycle until progressive disease, treatment limiting toxicity or death.	Paclitaxel+ Bevacizumab n=105 Participants Participants received paclitaxel 90 mg/m\^2 IV on Days 1, 8 and 15 and bevacizumab IV 10 mg/kg on Days 1 and 15 of a 28 day cycle until progressive disease, treatment limiting toxicity or death.
Percentage of Participants With an Objective Response - High Baseline Plasma VEGF-A ITT Population	32.8 percentage of participants Interval 24.22 to 41.3	54.3 percentage of participants Interval 44.76 to 63.81

SECONDARY outcome

Timeframe: Baseline, every 8 weeks until documented disease progression or clinical cut-off (up to 117.7 weeks)

Population: Number of participants analyzed=participants from ITT population who had an objective response.

Duration of response was defined as the time from the initial date of the objective response to documented disease progression or death (whichever occurred first). Objective response was defined as having a CR or PR according to a RECIST criteria v 1.1. CR was defined as disappearance of all target and non-target lesions and no new lesions, all pathological lymph nodes must have decreased to <10 mm in short axis and normalization of tumor marker level. PR was defined as at least a 30% decrease in the sum of diameters of target lesions (taking as reference the baseline sum diameters), no progression in non-target lesions, and no new lesions. Disease progression was defined as at least 20% increase in the sum of diameters of target lesions compared to smallest sum of diameters on-study and absolute increase of at least 5 mm, unequivocal progression of existing non-target lesions, or presence of new lesions. Analysis was performed using Kaplan Meier method.

Outcome measures

Measure	Paclitaxel+Placebo n=71 Participants Participants received paclitaxel 90 mg/m\^2 IV on Days 1, 8 and 15 and placebo matched to bevacizumab IV infusion on Days 1 and 15 of a 28 day cycle until progressive disease, treatment limiting toxicity or death.	Paclitaxel+ Bevacizumab n=109 Participants Participants received paclitaxel 90 mg/m\^2 IV on Days 1, 8 and 15 and bevacizumab IV 10 mg/kg on Days 1 and 15 of a 28 day cycle until progressive disease, treatment limiting toxicity or death.
Duration of Response - ITT Population	9.2 months Interval 7.4 to 11.5	9.5 months Interval 7.8 to 12.4

SECONDARY outcome

Timeframe: Baseline, every 8 weeks until documented disease progression or clinical cut-off (up to 111.3 weeks)

Population: Number of participants analyzed=participants from high baseline plasma VEGF-A ITT population who had an objective response.

Duration of response was defined as the time from the initial date of the objective response to documented disease progression or death (whichever occurred first). Objective response was defined as having a CR or PR according to a RECIST criteria v 1.1. CR was defined as disappearance of all target and non-target lesions and no new lesions, all pathological lymph nodes must have decreased to <10 mm in short axis and normalization of tumor marker level. PR was defined as at least a 30% decrease in the sum of diameters of target lesions (taking as reference the baseline sum diameters), no progression in non-target lesions, and no new lesions. Disease progression was defined at least 20% increase in the sum of diameters of target lesions compared to smallest sum of diameters on-study and absolute increase of at least 5 mm, unequivocal progression of existing non-target lesions, or presence of new lesions. Analysis was performed using Kaplan Meier method.

Outcome measures

Measure	Paclitaxel+Placebo n=38 Participants Participants received paclitaxel 90 mg/m\^2 IV on Days 1, 8 and 15 and placebo matched to bevacizumab IV infusion on Days 1 and 15 of a 28 day cycle until progressive disease, treatment limiting toxicity or death.	Paclitaxel+ Bevacizumab n=57 Participants Participants received paclitaxel 90 mg/m\^2 IV on Days 1, 8 and 15 and bevacizumab IV 10 mg/kg on Days 1 and 15 of a 28 day cycle until progressive disease, treatment limiting toxicity or death.
Duration of Response - High Baseline Plasma VEGF-A ITT Population	7.2 months Interval 5.6 to 9.5	8.1 months Interval 7.1 to 11.1

SECONDARY outcome

Timeframe: 1 year

Population: ITT Population.

Outcome measures

Measure	Paclitaxel+Placebo n=242 Participants Participants received paclitaxel 90 mg/m\^2 IV on Days 1, 8 and 15 and placebo matched to bevacizumab IV infusion on Days 1 and 15 of a 28 day cycle until progressive disease, treatment limiting toxicity or death.	Paclitaxel+ Bevacizumab n=239 Participants Participants received paclitaxel 90 mg/m\^2 IV on Days 1, 8 and 15 and bevacizumab IV 10 mg/kg on Days 1 and 15 of a 28 day cycle until progressive disease, treatment limiting toxicity or death.
Percentage of Participants Who Were Alive at 1 Year - ITT Population	80.94 percentage of participants	82.47 percentage of participants

SECONDARY outcome

Timeframe: 1 year

Population: High Baseline Plasma VEGF-A ITT Population

Outcome measures

Measure	Paclitaxel+Placebo n=124 Participants Participants received paclitaxel 90 mg/m\^2 IV on Days 1, 8 and 15 and placebo matched to bevacizumab IV infusion on Days 1 and 15 of a 28 day cycle until progressive disease, treatment limiting toxicity or death.	Paclitaxel+ Bevacizumab n=120 Participants Participants received paclitaxel 90 mg/m\^2 IV on Days 1, 8 and 15 and bevacizumab IV 10 mg/kg on Days 1 and 15 of a 28 day cycle until progressive disease, treatment limiting toxicity or death.
Secondary: Percentage of Participants Who Were Alive at 1 Year - High Baseline Plasma VEGF-A ITT Population	69.27 percentage of participants	80.96 percentage of participants

Adverse Events

Paclitaxel+Placebo

Serious events: 45 serious events

Other events: 225 other events

Deaths: 162 deaths

Paclitaxel+ Bevacizumab

Serious events: 66 serious events

Other events: 230 other events

Deaths: 161 deaths

Serious adverse events

Measure	Paclitaxel+Placebo n=233 participants at risk Participants received paclitaxel 90 mg/m\^2 IV on Days 1, 8 and 15 and placebo matched to bevacizumab IV infusion on Days 1 and 15 of a 28 day cycle until progressive disease, treatment limiting toxicity or death.	Paclitaxel+ Bevacizumab n=238 participants at risk Participants received paclitaxel 90 mg/m\^2 IV on Days 1, 8 and 15 and bevacizumab IV 10 mg/kg on Days 1 and 15 of a 28 day cycle until progressive disease, treatment limiting toxicity or death.
Injury, poisoning and procedural complications Femoral neck fracture	0.00% 0/233 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.42% 1/238 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Blood and lymphatic system disorders Anaemia	0.86% 2/233 • Number of events 3 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.42% 1/238 • Number of events 3 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Blood and lymphatic system disorders Febrile neutropenia	0.00% 0/233 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	1.7% 4/238 • Number of events 4 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Blood and lymphatic system disorders Leukopenia	0.43% 1/233 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.42% 1/238 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Blood and lymphatic system disorders Neutropenia	0.43% 1/233 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.00% 0/238 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Cardiac disorders Atrial fibrillation	0.43% 1/233 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.00% 0/238 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Cardiac disorders Left ventricular dysfunction	0.00% 0/233 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.42% 1/238 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Eye disorders Optic nerve disorder	0.43% 1/233 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.00% 0/238 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Eye disorders Visual acuity reduced	0.43% 1/233 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.00% 0/238 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Gastrointestinal disorders Abdominal distension	0.00% 0/233 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.42% 1/238 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Gastrointestinal disorders Abdominal pain	1.7% 4/233 • Number of events 6 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.84% 2/238 • Number of events 3 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Gastrointestinal disorders Colitis	0.00% 0/233 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.42% 1/238 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Gastrointestinal disorders Constipation	0.43% 1/233 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.42% 1/238 • Number of events 2 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Gastrointestinal disorders Diarrhoea	0.00% 0/233 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.84% 2/238 • Number of events 2 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Gastrointestinal disorders Duodenal obstruction	0.00% 0/233 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.42% 1/238 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Gastrointestinal disorders Dyspepsia	0.00% 0/233 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.42% 1/238 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Gastrointestinal disorders Enteritis	0.00% 0/233 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.42% 1/238 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Gastrointestinal disorders Gastric ulcer	0.00% 0/233 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.42% 1/238 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Gastrointestinal disorders Gastric ulcer haemorrhage	0.00% 0/233 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.42% 1/238 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Gastrointestinal disorders Gastric varices haemorrhage	0.00% 0/233 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.42% 1/238 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Gastrointestinal disorders Haematochezia	0.00% 0/233 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.42% 1/238 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Gastrointestinal disorders Nausea	0.00% 0/233 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	1.7% 4/238 • Number of events 4 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Gastrointestinal disorders Pancreatitis	0.00% 0/233 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.42% 1/238 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Gastrointestinal disorders Small intestinal obstruction	0.00% 0/233 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.42% 1/238 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Gastrointestinal disorders Vomiting	1.3% 3/233 • Number of events 3 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	1.7% 4/238 • Number of events 4 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
General disorders Asthenia	0.00% 0/233 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.42% 1/238 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
General disorders Death	0.00% 0/233 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.42% 1/238 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
General disorders Influenza like illness	0.00% 0/233 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.42% 1/238 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
General disorders Malaise	0.43% 1/233 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.00% 0/238 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
General disorders Mucosal inflammation	0.43% 1/233 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.00% 0/238 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
General disorders Pyrexia	0.00% 0/233 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.42% 1/238 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
General disorders Sudden death	0.43% 1/233 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.00% 0/238 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Hepatobiliary disorders Bile duct obstruction	0.00% 0/233 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.42% 1/238 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Hepatobiliary disorders Cholecystitis	0.43% 1/233 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.00% 0/238 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Hepatobiliary disorders Cholecystitis acute	0.43% 1/233 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.00% 0/238 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Hepatobiliary disorders Gallbladder pain	0.43% 1/233 • Number of events 3 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.00% 0/238 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Hepatobiliary disorders Hepatic failure	0.00% 0/233 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	1.3% 3/238 • Number of events 3 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Hepatobiliary disorders Hyperbilirubinaemia	0.00% 0/233 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.42% 1/238 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Immune system disorders Drug hypersensitivity	0.43% 1/233 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.00% 0/238 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Infections and infestations Abdominal wall abscess	0.00% 0/233 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.42% 1/238 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Infections and infestations Abscess	0.00% 0/233 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.42% 1/238 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Infections and infestations Abscess limb	0.43% 1/233 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.00% 0/238 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Infections and infestations Appendicitis	0.00% 0/233 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.84% 2/238 • Number of events 2 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Infections and infestations Cellulitis	0.00% 0/233 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	1.7% 4/238 • Number of events 6 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Infections and infestations Cholecystitis infective	0.00% 0/233 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.42% 1/238 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Infections and infestations Colonic abscess	0.00% 0/233 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.42% 1/238 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Infections and infestations Cystitis	0.43% 1/233 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.00% 0/238 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Infections and infestations Device related infection	0.86% 2/233 • Number of events 2 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	1.3% 3/238 • Number of events 3 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Infections and infestations Device related sepsis	0.00% 0/233 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.42% 1/238 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Infections and infestations Gastroenteritis	0.00% 0/233 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.42% 1/238 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Infections and infestations Infection	0.43% 1/233 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.00% 0/238 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Infections and infestations Influenza	0.00% 0/233 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.84% 2/238 • Number of events 2 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Infections and infestations Lung infection	0.43% 1/233 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.00% 0/238 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Infections and infestations Peritonitis	0.00% 0/233 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.42% 1/238 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Infections and infestations Pharyngotonsillitis	0.00% 0/233 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.42% 1/238 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Infections and infestations Pneumonia	1.3% 3/233 • Number of events 4 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	1.7% 4/238 • Number of events 4 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Infections and infestations Pneumonia necrotising	0.00% 0/233 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.42% 1/238 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Infections and infestations Sepsis	0.43% 1/233 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.84% 2/238 • Number of events 2 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Infections and infestations Sepsis syndrome	0.00% 0/233 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.42% 1/238 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Infections and infestations Septic shock	0.00% 0/233 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.42% 1/238 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Infections and infestations Upper respiratory tract infection	0.00% 0/233 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.42% 1/238 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Infections and infestations Urinary tract infection	0.43% 1/233 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.84% 2/238 • Number of events 2 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Infections and infestations Wound infection bacterial	0.00% 0/233 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.42% 1/238 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Injury, poisoning and procedural complications Femur fracture	0.00% 0/233 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.84% 2/238 • Number of events 2 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Injury, poisoning and procedural complications Hip fracture	0.43% 1/233 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.00% 0/238 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Injury, poisoning and procedural complications Humerus fracture	0.00% 0/233 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.84% 2/238 • Number of events 2 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Investigations Urine output decreased	0.00% 0/233 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.42% 1/238 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Metabolism and nutrition disorders Decreased appetite	0.86% 2/233 • Number of events 2 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.00% 0/238 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Metabolism and nutrition disorders Type 2 diabetes mellitus	0.43% 1/233 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.00% 0/238 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Musculoskeletal and connective tissue disorders Back pain	0.00% 0/233 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	1.7% 4/238 • Number of events 4 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Musculoskeletal and connective tissue disorders Neck pain	0.00% 0/233 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.42% 1/238 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Musculoskeletal and connective tissue disorders Osteonecrosis of jaw	0.00% 0/233 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.42% 1/238 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Cancer pain	0.43% 1/233 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.00% 0/238 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Gastric cancer	0.43% 1/233 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.00% 0/238 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Nervous system disorders Cerebral ischaemia	0.43% 1/233 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.00% 0/238 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Nervous system disorders Dementia	0.00% 0/233 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.42% 1/238 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Nervous system disorders Dizziness	0.43% 1/233 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.00% 0/238 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Nervous system disorders Hemiparesis	0.00% 0/233 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.42% 1/238 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Nervous system disorders Loss of consciousness	0.43% 1/233 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.00% 0/238 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Nervous system disorders Speech disorder	0.00% 0/233 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.42% 1/238 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Nervous system disorders Spinal cord compression	0.43% 1/233 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.00% 0/238 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Nervous system disorders Syncope	0.43% 1/233 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	1.3% 3/238 • Number of events 4 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Renal and urinary disorders Cystitis haemorrhagic	0.43% 1/233 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.00% 0/238 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Renal and urinary disorders Haematuria	0.43% 1/233 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.00% 0/238 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Respiratory, thoracic and mediastinal disorders Bronchospasm	0.43% 1/233 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.00% 0/238 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.86% 2/233 • Number of events 2 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.00% 0/238 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Respiratory, thoracic and mediastinal disorders Pleural effusion	0.86% 2/233 • Number of events 2 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.00% 0/238 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Respiratory, thoracic and mediastinal disorders Pneumonitis	0.00% 0/233 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.42% 1/238 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Respiratory, thoracic and mediastinal disorders Pneumothorax	0.43% 1/233 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.00% 0/238 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	0.00% 0/233 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	1.7% 4/238 • Number of events 4 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Respiratory, thoracic and mediastinal disorders Pulmonary oedema	0.86% 2/233 • Number of events 2 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.00% 0/238 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Skin and subcutaneous tissue disorders Pain of skin	0.43% 1/233 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.00% 0/238 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Skin and subcutaneous tissue disorders Skin haemorrhage	0.00% 0/233 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.42% 1/238 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Vascular disorders Aortic stenosis	0.43% 1/233 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.00% 0/238 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Vascular disorders Deep vein thrombosis	0.86% 2/233 • Number of events 2 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.00% 0/238 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Vascular disorders Embolism venous	0.43% 1/233 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.00% 0/238 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Vascular disorders Superior vena cava syndrome	0.00% 0/233 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.42% 1/238 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Vascular disorders Venous thrombosis limb	0.43% 1/233 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.00% 0/238 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Cardiac disorders ACUTE CORONARY SYNDROME	0.00% 0/233 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.42% 1/238 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Cardiac disorders CARDIAC FAILURE CONGESTIVE	0.43% 1/233 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.00% 0/238 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Eye disorders CATARACT	0.43% 1/233 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.00% 0/238 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
General disorders CATHETER SITE ERYTHEMA	0.00% 0/233 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.42% 1/238 • Number of events 2 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Immune system disorders ANAPHYLACTIC REACTION	0.00% 0/233 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.42% 1/238 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Infections and infestations VIRAL INFECTION	0.00% 0/233 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.42% 1/238 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Infections and infestations CATHETER SITE INFECTION	0.43% 1/233 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.00% 0/238 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Infections and infestations KLEBSIELLA SEPSIS	0.43% 1/233 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.00% 0/238 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Infections and infestations SOFT TISSUE INFECTION	0.00% 0/233 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.42% 1/238 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Infections and infestations URINARY TRACT INFECTION BACTERIAL	0.43% 1/233 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.00% 0/238 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Injury, poisoning and procedural complications ROAD TRAFFIC ACCIDENT	0.43% 1/233 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.00% 0/238 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Injury, poisoning and procedural complications STERNAL FRACTURE	0.00% 0/233 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.42% 1/238 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Injury, poisoning and procedural complications WOUND DEHISCENCE	0.00% 0/233 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.42% 1/238 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Metabolism and nutrition disorders HYPOKALAEMIA	0.00% 0/233 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.42% 1/238 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Metabolism and nutrition disorders HYPONATRAEMIA	0.00% 0/233 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.42% 1/238 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Metabolism and nutrition disorders LACTIC ACIDOSIS	0.00% 0/233 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.42% 1/238 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Vascular disorders ARTERIAL THROMBOSIS	0.00% 0/233 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	0.42% 1/238 • Number of events 1 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).

Other adverse events

Measure	Paclitaxel+Placebo n=233 participants at risk Participants received paclitaxel 90 mg/m\^2 IV on Days 1, 8 and 15 and placebo matched to bevacizumab IV infusion on Days 1 and 15 of a 28 day cycle until progressive disease, treatment limiting toxicity or death.	Paclitaxel+ Bevacizumab n=238 participants at risk Participants received paclitaxel 90 mg/m\^2 IV on Days 1, 8 and 15 and bevacizumab IV 10 mg/kg on Days 1 and 15 of a 28 day cycle until progressive disease, treatment limiting toxicity or death.
Blood and lymphatic system disorders Anaemia	16.7% 39/233 • Number of events 82 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	16.4% 39/238 • Number of events 63 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Blood and lymphatic system disorders Leukopenia	6.0% 14/233 • Number of events 42 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	7.1% 17/238 • Number of events 41 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Blood and lymphatic system disorders Neutropenia	21.5% 50/233 • Number of events 124 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	32.4% 77/238 • Number of events 254 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Gastrointestinal disorders Abdominal pain	7.3% 17/233 • Number of events 30 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	8.4% 20/238 • Number of events 27 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Gastrointestinal disorders Abdominal pain upper	5.6% 13/233 • Number of events 14 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	5.5% 13/238 • Number of events 16 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Gastrointestinal disorders Constipation	21.5% 50/233 • Number of events 70 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	28.2% 67/238 • Number of events 108 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Gastrointestinal disorders Diarrhoea	30.9% 72/233 • Number of events 128 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	37.0% 88/238 • Number of events 189 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Gastrointestinal disorders Dyspepsia	6.9% 16/233 • Number of events 20 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	9.7% 23/238 • Number of events 40 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Gastrointestinal disorders Nausea	32.2% 75/233 • Number of events 205 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	41.6% 99/238 • Number of events 310 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Gastrointestinal disorders Stomatitis	11.2% 26/233 • Number of events 35 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	17.6% 42/238 • Number of events 75 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Gastrointestinal disorders Toothache	3.4% 8/233 • Number of events 9 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	6.3% 15/238 • Number of events 16 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Gastrointestinal disorders Vomiting	15.5% 36/233 • Number of events 63 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	19.7% 47/238 • Number of events 96 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
General disorders Asthenia	15.5% 36/233 • Number of events 50 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	13.4% 32/238 • Number of events 62 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
General disorders Fatigue	31.8% 74/233 • Number of events 123 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	37.0% 88/238 • Number of events 156 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
General disorders Oedema peripheral	18.0% 42/233 • Number of events 57 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	17.2% 41/238 • Number of events 56 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
General disorders Pyrexia	12.0% 28/233 • Number of events 37 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	14.3% 34/238 • Number of events 59 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Infections and infestations Bronchitis	5.2% 12/233 • Number of events 12 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	4.6% 11/238 • Number of events 14 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Infections and infestations Nasopharyngitis	15.5% 36/233 • Number of events 65 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	10.1% 24/238 • Number of events 54 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Infections and infestations Paronychia	3.0% 7/233 • Number of events 9 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	5.5% 13/238 • Number of events 13 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Infections and infestations Upper respiratory tract infection	4.7% 11/233 • Number of events 14 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	10.5% 25/238 • Number of events 26 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Infections and infestations Urinary tract infection	6.9% 16/233 • Number of events 22 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	14.7% 35/238 • Number of events 47 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Investigations Alanine aminotransferase increased	7.3% 17/233 • Number of events 21 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	8.8% 21/238 • Number of events 37 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Investigations Aspartate aminotransferase increased	6.9% 16/233 • Number of events 19 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	8.8% 21/238 • Number of events 32 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Investigations Neutrophil count decreased	8.6% 20/233 • Number of events 100 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	6.3% 15/238 • Number of events 56 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Investigations White blood cell count decreased	6.9% 16/233 • Number of events 84 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	8.8% 21/238 • Number of events 87 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Metabolism and nutrition disorders Decreased appetite	18.0% 42/233 • Number of events 65 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	23.1% 55/238 • Number of events 91 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Metabolism and nutrition disorders Hypokalaemia	4.3% 10/233 • Number of events 13 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	6.3% 15/238 • Number of events 22 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Musculoskeletal and connective tissue disorders Arthralgia	22.7% 53/233 • Number of events 86 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	22.3% 53/238 • Number of events 91 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Musculoskeletal and connective tissue disorders Back pain	13.3% 31/233 • Number of events 42 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	10.9% 26/238 • Number of events 32 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Musculoskeletal and connective tissue disorders Bone pain	8.6% 20/233 • Number of events 32 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	4.6% 11/238 • Number of events 17 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Musculoskeletal and connective tissue disorders Myalgia	12.0% 28/233 • Number of events 60 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	18.1% 43/238 • Number of events 83 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Musculoskeletal and connective tissue disorders Pain in extremity	9.0% 21/233 • Number of events 23 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	9.7% 23/238 • Number of events 32 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Nervous system disorders Dizziness	10.3% 24/233 • Number of events 25 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	11.8% 28/238 • Number of events 33 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Nervous system disorders Dysgeusia	9.4% 22/233 • Number of events 24 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	13.9% 33/238 • Number of events 43 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Nervous system disorders Headache	18.9% 44/233 • Number of events 71 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	21.4% 51/238 • Number of events 85 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Nervous system disorders Neuropathy peripheral	21.5% 50/233 • Number of events 67 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	19.7% 47/238 • Number of events 72 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Nervous system disorders Paraesthesia	7.3% 17/233 • Number of events 21 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	5.0% 12/238 • Number of events 14 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Nervous system disorders Peripheral sensory neuropathy	36.1% 84/233 • Number of events 107 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	38.7% 92/238 • Number of events 129 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Psychiatric disorders Anxiety	6.4% 15/233 • Number of events 15 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	3.4% 8/238 • Number of events 8 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Psychiatric disorders Insomnia	8.6% 20/233 • Number of events 24 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	14.7% 35/238 • Number of events 46 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Renal and urinary disorders Proteinuria	11.2% 26/233 • Number of events 33 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	13.4% 32/238 • Number of events 53 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Respiratory, thoracic and mediastinal disorders Cough	12.9% 30/233 • Number of events 38 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	18.1% 43/238 • Number of events 59 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Respiratory, thoracic and mediastinal disorders Dysphonia	2.1% 5/233 • Number of events 5 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	8.0% 19/238 • Number of events 24 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Respiratory, thoracic and mediastinal disorders Dyspnoea	12.9% 30/233 • Number of events 33 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	13.9% 33/238 • Number of events 41 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Respiratory, thoracic and mediastinal disorders Epistaxis	20.6% 48/233 • Number of events 77 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	40.8% 97/238 • Number of events 158 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain	6.0% 14/233 • Number of events 15 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	7.6% 18/238 • Number of events 23 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Respiratory, thoracic and mediastinal disorders Rhinorrhoea	1.3% 3/233 • Number of events 4 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	8.4% 20/238 • Number of events 26 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Skin and subcutaneous tissue disorders Alopecia	62.2% 145/233 • Number of events 159 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	58.8% 140/238 • Number of events 149 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Skin and subcutaneous tissue disorders Dry skin	3.0% 7/233 • Number of events 7 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	7.6% 18/238 • Number of events 20 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Skin and subcutaneous tissue disorders Nail discolouration	7.7% 18/233 • Number of events 18 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	13.9% 33/238 • Number of events 37 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Skin and subcutaneous tissue disorders Nail disorder	5.6% 13/233 • Number of events 13 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	5.5% 13/238 • Number of events 14 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Skin and subcutaneous tissue disorders Onychomadesis	2.6% 6/233 • Number of events 6 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	6.3% 15/238 • Number of events 17 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Skin and subcutaneous tissue disorders Pruritis	4.3% 10/233 • Number of events 12 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	6.3% 15/238 • Number of events 17 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Skin and subcutaneous tissue disorders Rash	13.3% 31/233 • Number of events 36 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	24.4% 58/238 • Number of events 113 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Vascular disorders Hot flush	4.3% 10/233 • Number of events 30 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	6.3% 15/238 • Number of events 17 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Vascular disorders Hypertension	12.9% 30/233 • Number of events 83 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	30.7% 73/238 • Number of events 109 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Infections and infestations SINUSITIS	3.4% 8/233 • Number of events 12 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	5.0% 12/238 • Number of events 15 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Investigations WEIGHT DECREASED	2.1% 5/233 • Number of events 5 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	5.0% 12/238 • Number of events 13 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Musculoskeletal and connective tissue disorders NECK PAIN	1.3% 3/233 • Number of events 5 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	5.0% 12/238 • Number of events 13 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).
Musculoskeletal and connective tissue disorders MUSCULOSKELETAL PAIN	2.1% 5/233 • Number of events 8 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).	5.0% 12/238 • Number of events 14 • From the first dose of study drug through 30 days after the last dose of study drug or clinical cut-off (up to 115.1 weeks) Safety population: All randomized participants who received at least one full or partial dose of any component of the study treatment (bevacizumab, placebo, or paclitaxel).

Additional Information

Medical Communications

Hoffmann-LaRoche

Phone: 800 821-8590

Email: genentech@druginfo.com

Results disclosure agreements

• Principal investigator is a sponsor employee The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.
• Publication restrictions are in place

Restriction type: OTHER